These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64 related articles for article (PubMed ID: 2959046)
21. [Redistribution of the coronary blood flow, functional improvement of the ischemic myocardium and reduction of the size of an experimental infarction by molsidomine]. Berdeaux A; Giudicelli JF Ann Cardiol Angeiol (Paris); 1983 Dec; 32(8):511-5. PubMed ID: 6364947 [TBL] [Abstract][Full Text] [Related]
22. Synergized activation of human platelets by epinephrine and platelet-activating factor-acether is adenosine diphosphate and thromboxane A2-independent. Vargaftig BB; Fouque F; Joseph D; Odiot J; Benveniste J Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():429-33. PubMed ID: 6221558 [No Abstract] [Full Text] [Related]
23. Inhibition by nitroglycerin of canine platelet aggregation and cyclic flow reductions in stenosed coronary arteries. Tanaka T; Morishima Y; Watanabe K; Takahashi M; Shibano T Methods Find Exp Clin Pharmacol; 1995 Dec; 17(10):693-700. PubMed ID: 9053590 [TBL] [Abstract][Full Text] [Related]
24. Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory activity. Murakami M; Kinukawa M; Kanazawa T; Maruyama K; Miyagi M; Miyata H; Ujiie A J Pharmacol Exp Ther; 1996 Nov; 279(2):877-83. PubMed ID: 8930195 [TBL] [Abstract][Full Text] [Related]
25. Thromboxane A2, prostacyclin and aspirin: effects on vascular tone and platelet aggregation. Smith JB; Araki H; Lefer AM Circulation; 1980 Dec; 62(6 Pt 2):V19-25. PubMed ID: 7002350 [TBL] [Abstract][Full Text] [Related]
26. Inhibition of platelet 5-HT secretion and of 5-HT induced vasoconstriction by paracetamol. Verheggen R; Schrör K Prog Clin Biol Res; 1987; 242():271-6. PubMed ID: 3671387 [No Abstract] [Full Text] [Related]
27. Analysis of the biological activity of azoprostanoids in human platelets. Gorman RR; Shebuski RJ; Aiken JW; Bundy GL Fed Proc; 1981 May; 40(7):1997-2000. PubMed ID: 7014259 [TBL] [Abstract][Full Text] [Related]
28. Pharmacologic characterization of human and canine thromboxane A2/prostaglandin H2 receptors in platelets and blood vessels: evidence for different receptors. Mais DE; Saussy DL; Chaikhouni A; Kochel PJ; Knapp DR; Hamanaka N; Halushka PV J Pharmacol Exp Ther; 1985 May; 233(2):418-24. PubMed ID: 2987481 [TBL] [Abstract][Full Text] [Related]
29. The biological role of thromboxane A2 in the process of hemostasis and thrombosis; pharmacology and perspectives of therapeutical use of thromboxane synthetase inhibitors and receptor PGH2/TXA2 antagonists. Radomski M Acta Physiol Pol; 1985; 36(3):153-64. PubMed ID: 3915630 [TBL] [Abstract][Full Text] [Related]
35. [Clinical and experimental study on anti-platelet aggregation effect of d-catechin]. He YS Zhong Xi Yi Jie He Za Zhi; 1982 Jan; 2(1):15-8. PubMed ID: 6219793 [No Abstract] [Full Text] [Related]
36. Re: Cyclosporine A nephrotoxicity the role of thromboxane A2. Prostaglandins Leukot Essent Fatty Acids; 1988; 33(3):253-5. PubMed ID: 3237735 [No Abstract] [Full Text] [Related]
37. The molecular, biochemical and human pharmacology of thromboxane A2 in renal disease. FitzGerald GA; Murray R; Price P; Catella F Adv Exp Med Biol; 1989; 259():325-60. PubMed ID: 2516412 [No Abstract] [Full Text] [Related]